Temozolomide is an active agent in children with recurrent medulloblastoma/primitive neuroectodermal tumor: an Italian multi-institutional phase II trial
Background The aim of this study was to assess the objective response rate (ORR) of
children and young adults with recurrent medulloblastoma/primitive neuroectodermal tumor …
children and young adults with recurrent medulloblastoma/primitive neuroectodermal tumor …
Temozolomide with irinotecan versus temozolomide, irinotecan plus bevacizumab for recurrent medulloblastoma of childhood: Report of a COG randomized Phase II …
AS Levy, M Krailo, S Chi, D Villaluna… - Pediatric blood & …, 2021 - Wiley Online Library
Background: Approximately 30% of children with medulloblastoma (MB) experience
recurrence, which is usually incurable. This study compared the overall survival (OS) of …
recurrence, which is usually incurable. This study compared the overall survival (OS) of …
Phase I study of temozolomide combined with oral etoposide in children with recurrent or progressive medulloblastoma
A Ruggiero, D Rizzo, G Attinà, I Lazzareschi… - European Journal of …, 2010 - Elsevier
BACKGROUND: The prognosis of recurrent or progressive medulloblastoma (MB) is still
poor. This study was designed to investigate the potential therapeutic benefit of combination …
poor. This study was designed to investigate the potential therapeutic benefit of combination …
Phase 2 study of temozolomide in children and adolescents with recurrent central nervous system tumors: a report from the Children's Oncology Group
HS Nicholson, CS Kretschmar, M Krailo… - … Journal of the …, 2007 - Wiley Online Library
BACKGROUND. Effective chemotherapy is lacking for most types of central nervous system
(CNS) tumors in children. Temozolomide, an agent with activity against adult brain tumors …
(CNS) tumors in children. Temozolomide, an agent with activity against adult brain tumors …
Phase II study of irinotecan in combination with temozolomide (TEMIRI) in children with recurrent or refractory medulloblastoma: a joint ITCC and SIOPE brain tumor …
J Grill, B Geoerger, L Gesner, D Perek… - Neuro …, 2013 - academic.oup.com
Background This multicenter phase II study investigated temozolomide+ irinotecan (TEMIRI)
treatment in children with relapsed or refractory medulloblastoma. Methods Patients …
treatment in children with relapsed or refractory medulloblastoma. Methods Patients …
Efficacy of temozolomide for recurrent embryonal brain tumors in children
CH Wang, TR Hsu, TT Wong, KP Chang - Child's Nervous System, 2009 - Springer
Objective The salvage therapy of recurrent embryonal brain tumors in children is
disappointing. Temozolomide is a newly developed chemotherapeutic agent in central …
disappointing. Temozolomide is a newly developed chemotherapeutic agent in central …
Temozolomide in resistant or relapsed pediatric solid tumors
L De Sio, GM Milano, A Castellano… - Pediatric blood & …, 2006 - Wiley Online Library
Purpose We report the off‐label study aimed at investigating the use of temozolomide (TMZ)
as single agent in relapsed or resistant pediatric solid tumors. The drug was administered at …
as single agent in relapsed or resistant pediatric solid tumors. The drug was administered at …
Phase II study of temozolomide in relapsed or refractory high-risk neuroblastoma: a joint Société Française des Cancers de l'Enfant and United Kingdom Children …
H Rubie, J Chisholm, AS Defachelles… - Journal of clinical …, 2006 - ascopubs.org
Purpose To determine the response rate (RR) of neuroblastoma (NB) in children to
temozolomide (TMZ), and evaluate the duration of response and tolerance of the drug in this …
temozolomide (TMZ), and evaluate the duration of response and tolerance of the drug in this …
Reirradiation and concomitant metronomic temozolomide: an efficient combination for local control in medulloblastoma disease?
L Padovani, N Andre, JC Gentet… - Journal of pediatric …, 2011 - journals.lww.com
Medulloblastoma (MB) is the most common malignant pediatric brain tumor and a rare
adulthood tumor. Twenty percent to 30% of patients relapses and displays a poor prognosis …
adulthood tumor. Twenty percent to 30% of patients relapses and displays a poor prognosis …
Response to bevacizumab, irinotecan, and temozolomide in children with relapsed medulloblastoma: a multi-institutional experience
D Aguilera, C Mazewski, J Fangusaro… - Child's nervous …, 2013 - Springer
Purpose Chemotherapy for relapsed medulloblastoma has been inadequate, and most
patients succumb to disease. Methods We retrospectively reviewed nine cases of relapsed …
patients succumb to disease. Methods We retrospectively reviewed nine cases of relapsed …